Consenso sobre Linfomas - Sociedad Argentina de Dermatología

41. Nistico S; Costanzo, A; Saraceno, R; Chimenti, S. Efficacy of monochromatic
excimer laser radiation (308nm) in the treatment of early stage mycosis fungoides.
British Journal of Dermatology 2004; 151:877-879
42. Olsen E et al. Pivotal phase III trial of two dose levels of denileukin diftitox for
the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19: 376-388
43. Oyama Y et al. High- dose therapy and bone marrow transplantation in
cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 2003;17:1475-1483
44. Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C. Intralesional
rituximab for cutaneous B-cell lymphoma. Br J Dermatol. 2001; 144:1239-1243.
45. Pichardo DA et al. Cutaneous T-cell lymphoma: a paradigm for biological
therapies.
Leuk Lymphoma. 2004; 45:1755-1765.
46. Pimpinelli N, Vallecchi C. Local orthovolt radiotherapy in primary cutaneous B-
cell lymphomas: results in a series of 115 patients. Skin Cancer. 1999; 14:219-224.
47. Querfeld, Ch; Rosen, S; Kuzel, T; Kirby, K. Long- term follow-up of patients
with early-stage Cutaneous T-Cell Lymphoma who achieve complete remission with
Psoralen plus UVA monotherapy. Arch Dermatol. 2005; 141:305-311.
48. Richardson S., Budgin J., et al. Low-Dose Bexarotene and Low-Dose interferon
alpha-2b for adult T-cell Leukemia/Lymphoma Associated with human T-
Lymphotropic virus I. Arch. Dermatol. 2005; 141:301-304.
49. Rijlaarsdam JU, Toonstra J, Meijer OW, Noordijk EM, Willemze R. Treatment
of primary cutaneous B-cell lymphomas of follicular center cell origin: a clinical
follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin
Oncol. 1996; 14:549-555.
50. Rook AH et al. Cytokine therapy of cutaneous T-cell lymphoma: interferons,
interleukin-12 and interleukin-2. Hematol Oncol Clin N Am 2003; 17:1435-1448.
51. Rosen, S, Foss, F. Chemotherapy for mycosis fungoides and the Sezary
syndrome. Hematol Oncol Clin North Am 1995; 9:1109-1116.
52. Sarris, AH, Phan, A, Duvic, M, et al. Trimetrexate in relapsed T-cell lymphoma
with skin involvement. J Clin Oncol 2002; 20:2876.
53. Shistik G et al. Follicular mycosis fungoides: successful treatment with oral
bexarotene. J Drugs Dermatol. 2004; 3:301-304.
54. Smith BD, Glusac EJ, McNiff JM, et al. Primary cutaneous B-cell lymphoma
treated with radiotherapy: a comparison of the European Organization for Research and
Treatment of Cancer and the WHO classification systems. J Clin Oncol. 2004; 22:634-
639.
55. Soda R, Constanzo A, Cantonetti M, Orlandi A, Bianchi L, Chimenti S.
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with
rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol. 2001;
81:207-208.
56. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical
trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in
patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998; 92:35783581.
57. Suchin, KR, Cucchiara, AJ, Gottleib, SL, et al. Treatment of cutaneous T-cell
lymphoma with combined immunomodulatory therapy: a 14-year experience at a single
institution. Arch Dermatol 2002; 138:1054-1060.
58. Vakeva, L; Sarna, S; Vaalasti, A; Pukkala, E. A Retrospective Study of the
Probability of Evolution of Parapsoriasis en Plaques into Mycosis Fungoides. Acta
Derm Venereol 2005; 85:318-323